Endocrine Abstracts

Sclerostin is a major negative regulator of osteoblastic activity at tissue level. Serum sclerostin levels have been associated with bone mineral density and increased fracture risk. However, the relation between serum levels and expression on tissue levels is unknown. The aim of this study was to investigate this relationship. We used serum samples and bone biopsies from 26 patients that were available from a large randomised clinical trial, investigating with the effect of r...